M.D. Anderson and AstraZeneca form neuropathic pain alliance

February 1, 2008

M.D. Anderson Cancer Center and AstraZeneca will collaborate to help advance the understanding of neuropathic pain caused by cancer chemotherapy.

HOUSTON—M.D. Anderson Cancer Center and AstraZeneca will collaborate to help advance the understanding of neuropathic pain caused by cancer chemotherapy. The alliance will focus on identifying neurobiological differences between cancer patients who develop such pain and those who do not, and better understanding the mechanisms through which chemotherapies cause peripheral nerve dysfunctions.